Crossmark

Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel

Crossref DOI link: https://doi.org/10.1186/s12876-018-0803-1

Published Online: 2018-05-31

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Quaas, A. https://orcid.org/0000-0002-3537-6011
Waldschmidt, D.

Alakus, H.

Zander, T.

Heydt, C.

Goeser, T.

Daheim, M.

Kasper, P.

Plum, P.

Bruns, C.

Brunn, A.

Roth, W.

Hartmann, N.

Bunck, A.

Schmidt, M.

Göbel, H.

Tharun, L.

Buettner, R.

Merkelbach-Bruse, S.
License Information

Text and Data Mining valid from 2018-05-31
More Information

Article History

Received: 21 October 2017

Accepted: 23 May 2018

First Online: 31 May 2018

Ethics approval and consent to participate

: Procedures were followed as outlined in accordance with ethical standards formulated in the Helsinki Declaration 1975 (and revised in 1983). Informed consent was obtained prior to participation in this study with approval by the Ethics Committee at the University Hospital, Cologne (reference number: 13–091). This approval was necessary due to gene analysis made in this study.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images, and is available on request.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.